GlaxoSmithKline Twinrix
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The combination hepatitis A/B vaccine is approved May 11 as a three-dose regimen for the "active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus." Twinrix will be available in June. As a postmarketing commitment, the firm will do a comparative safety study of Twinrix against its individual components, GSK's Havrix (hepatitis A vaccine) and Engerix-B (recombinant hepatitis B vaccine). Glaxo is planning accelerated dosing studies in the U.S. to evaluate the vaccine for a two-dose regimen, with a BLA filing slated for 2002
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.